Arc-1 Tirzepatide Review: Cost, Per-Dose Pricing & Honest Verdict (2026)

Arc-1 sells compounded semaglutide and tirzepatide as per-dose purchases rather than monthly subscriptions — a genuinely different model from most compounded providers. This review's live check of arc-1.co was blocked by a rate limit, so the figures below rest on prior research. Every fact here comes from the company's own published program.

What Arc-1 is

Arc-1 sells GLP-1 medication as per-dose purchases, rather than a recurring subscription or membership — a structural difference from most compounded providers in this category. It also carries a broader longevity formulary, including rapamycin, NAD+, and sermorelin. This review's own live attempt to independently verify the site returned a rate-limit response — the figures here reflect prior research, not our own check.

What Arc-1 costs — and why the entry price isn't the whole story

Arc-1 advertises compounded semaglutide from $249.99 and tirzepatide from $299.99, alongside a 25% off plus free shipping promotion. The entry figure is a floor, not a flat rate: per that same research, semaglutide's 2.5mg dose actually runs $549.99/month, and tirzepatide's 7.5mg dose runs $399.99/month — the per-dose price genuinely climbs as you titrate up, so the advertised "from" figure applies only to the lowest starting dose.

The brand-vs-compounded question

Arc-1 dispenses compounded tirzepatide and semaglutide, not FDA-approved branded products. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Arc-1's real strengths: per-dose purchasing with no subscription or membership required, a broader longevity formulary beyond just GLP-1, a 25% off plus free shipping promotion, and a LegitScript Certified badge displayed on product pages. The trade-offs: no legal entity name or address disclosed, state availability not disclosed, no named clinicians or pharmacy partners, and — the most important detail — per-dose pricing climbs meaningfully with dose, so the advertised entry price is a floor at the lowest starting dose, not the price you'll pay once titrated to a therapeutic dose. As with any GLP-1 program, calculate the price at your expected therapeutic dose, not the lowest advertised figure, before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Arc-1's no-subscription, per-dose model is a real structural difference, but the advertised entry price ($299.99) applies only to the lowest dose — a therapeutic 7.5mg dose runs $399.99/month, meaningfully higher. If you want genuinely flat pricing that doesn't climb with dose, compare it against bmiMD or CoreAge Rx. See our best tirzepatide providers ranking for the full field.